L. Goldstein

发表

Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis

Steven J. M. Jones, S. Wiseman, A. Melck, 2008, Annals of Surgical Oncology.

Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases

L. Goldstein, A. Gown, M. Rijn, 2008, Breast Cancer Research and Treatment.

A role for the MHC class I‐like Mill molecules in nutrient metabolism and wound healing

Martin Wolfson, L. Goldstein, Randal R Ketchem, 2008, Immunology and cell biology.

Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.

Karen A Gelmon, David Huntsman, C Blake Gilks, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 in well differentiated breast cancer: is testing necessary?

Mehrdad Nadji, Allen M. Gown, L. Goldstein, 2008, Breast Cancer Research and Treatment.

Concordance between human epidermal growth factor receptor 2 testing by reverse transcriptase polymerase chain reaction and fluorescent in situ hybridization.

L. Goldstein, A. Gown, H. Hwang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to Hanna et al.

L. Goldstein, A. Gown, S. Kussick, 2008, Modern Pathology.

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.

L. Goldstein, R. Hull, S. Subramanian, 2013, American journal of physiology. Endocrinology and metabolism.

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

L. Goldstein, W. Fridman, H. Brandwein, 2012, Cancer Immunology, Immunotherapy.

One year of sitagliptin treatment does not result in exocrine pancreatic pathology in mice

L. Goldstein, R. Hull, S. Subramanian, 2011 .

Utility of a Comprehensive Immunohistochemical Panel in the Differential Diagnosis of Spindle Cell Lesions of the Urinary Bladder

L. Goldstein, A. Gown, A. Folpe, 2009, The American journal of surgical pathology.

Multivariate analysis of expression of the microtubule-associated protein, tau, predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim.

L. Goldstein, A. Gown, P. Porter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.

Steven J. M. Jones, S. Wiseman, H. Masoudi, 2007, Archives of surgery.

Thyroid Transcription Factor-1 Expression in Breast Carcinomas

L. Goldstein, A. Gown, S. Schnitt, 2010, The American journal of surgical pathology.

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

L. Goldstein, A. Gown, S. Shak, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

L. Goldstein, A. Gown, T. Barry, 2008, Modern Pathology.

HER-2 testing in breast cancer using parallel tissue-based methods.

L. Goldstein, A. Gown, R. Livingston, 2004, JAMA.

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

L. Goldstein, A. Gown, H. Hwang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients

L. Goldstein, H. Kaplan, J. Malmgren, 2010, Cancer management and research.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Jong-Hyeon Jeong, Hanna Bandos, Debora Fumagalli, 2013, Journal of the National Cancer Institute.

Amplification involving the CEP17 region may lead to false negative results of HER2 gene amplification by FISH.

L. Goldstein, A. Gown, T. Barry, 2009 .

Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.

L. Goldstein, A. Ho, S. Glück, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relationship Between Clinical and Pathologic Features of Ductal Carcinoma In Situ and Patient Age: An Analysis of 657 Patients

L. Goldstein, A. Gown, S. Fletcher, 2009, The American journal of surgical pathology.

Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients.

L. Goldstein, J. Malmgren, M. Atwood, 2010, Cancer Management and Research.

Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction.

L. Goldstein, S. Lee, J. Sninsky, 1988, The Journal of infectious diseases.

Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and preliminary use in diagnosis of cytomegalovirus pneumonia

L. Goldstein, R. Hackman, R. Nowinski, 1982, Infection and immunity.